Home/Pipeline/Obesity Program (GPR75)

Obesity Program (GPR75)

Obesity

Lead OptimizationActive

Key Facts

Indication

Obesity

Phase

Lead Optimization

Status

Active

Company

Confo Therapeutics

About Confo Therapeutics

Confo Therapeutics is a Belgian clinical-stage biotech pioneering a unique approach to drug discovery for GPCRs, a historically challenging but highly druggable target class. The company's proprietary platform enables the development of both small molecules and antibodies, with a pipeline focused on metabolic and endocrine conditions, including neuropathic pain, obesity, and post-bariatric hypoglycemia. Backed by a €60M Series B financing and strategic partnerships, Confo is advancing its lead candidate, CFTX-1554, into Phase 1 while expanding its early-stage pipeline. The company operates as a private, pre-revenue entity leveraging its technology for internal programs and potential collaborations.

View full company profile

Therapeutic Areas

Metabolic Diseases Endocrine Diseases Pain

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active